linjc16/ctgov huggingface dataset:
Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.

Study Overview
=================
Brief Summary
-----------------
Background: Procalcitonin (PCT) is a biomarker that has been proposed as a helpful tool in inflammatory Clinique cases specially patient with pulmonary bacterienne infection . Materials and methods the investigatore had retrospectively reviewed the electronic records and lists of all 582 COVID-19 patients admitted on the ICU of Hospital university Mohammed VI , Oujda. Between 01 juin 2020 and 31juanary 2021 , and analyzed the relation of PCT value and mortality at 30 days until we can defined a cut off Procalcitonine to use as a marker of severity and high mortality .

Detailed Description
-----------------
Our objective is to assess the relationship between Procalcitonin and 30-day mortality in patients admitted to the resuscitation department of the Mohammed VI University Hospital Center, Oujda, Morocco, infected by the SARS COV 2 Virus .

Official Title
-----------------
Procalcitonin Level and the High Risk of Mortality in 30 Days , in Critically Ill Patients Infected by SARS-CoV-2, Experience of a North African Hospital University , Cases Series.

Conditions
-----------------
the Relationship Between Procalcitonin and 30-day Mortality in COVID Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of SARS COV2 infection needed admission in ICU . Exclusion Criteria: patient under 15 ans

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Procalcitonine analysed<br>The invistagatore had analysed the Procalcitonine of patient that survived and the non Survived frome COVID infection in Intensive care departement | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Procalcitonin is a marker of mortality | as a cutoff 0.5 ng/ml Procalcitonin could be used as mortality factors | through study completion, an average of 8 mounths | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID, Procalcitonine, Mortality
Impact of Stent Length and Diameter on Patients Undergoing Primary PCI

Study Overview
=================
Brief Summary
-----------------
The goal of the study is to evaluate the Impact of coronary stent length and/or diameter in patients with ST segment myocardial infarction undergoing primary PCI, on Short term clinical outcomes.

Detailed Description
-----------------
ST segment elevation myocardial infarction is serious condition to the blood supply to the heart muscle. Rapid reperfusion of the ischemic myocardium using percutaneous coronary intervention (PCI) is the standard treatment for acute myocardial infarction (MI) to rescue the ischemic myocardium and reduce infarction size. There are two types of stents: Drug-eluting stent which achieving local drug delivery to the injured blood vessel at the time of intervention, a drug is released from a polymer coating or loaded directly onto the stent (2). This is the best one. Bare metal stent is the old one and not effective as DES in reducing vascular restenosis by suppressing smooth muscle cell (SMC) proliferation. The management of long coronary lesions by percutaneous coronary intervention (PCI) has become increasingly important because of the rising incidence of long or complex lesions in aging populations (3) Stent length has been considered as an important predictor of adverse events after PCI. The exact impact of lesion length on the short- and long-term clinical outcomes of DES implantations is not clear yet. Myocardial necrosis complicates one-third of percutaneous coronary intervention (PCI) and may adversely affect the outcome(4)

Official Title
-----------------
Impact of Stent Length and Diameter on Short Term Outcomes in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary PCI.

Conditions
-----------------
ST-segment Elevation Myocardial Infarction (STEMI)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ST segment myocardial infarction who are eligible for PCI. All categories (all age groups and both sex groups) Exclusion Criteria: Patients with previous PCI. Patients of ectatic lesions. Patients with with multi vessel disease and suitable for CABG. Patients with complex lesions including bifurcational lesions and LM stenting.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prognosis of patients with ST segment myocardial infarction undergoing primary PCI | prognosis will be measured with ECG and ECHO | 3 months |
The Effectiveness of Single Antibiotic Paste Nitrofurantoin Versus Double Antibiotic Paste

Study Overview
=================
Brief Summary
-----------------
In our study, we used nitrofurantoin as a root canal medication in patients suffering from symptomatic irreversible pulpitis in alleviating pain compared with double antibiotic paste.

Detailed Description
-----------------
This study aims to compare the efficacy in alleviating pain between intracanal medicaments Nitrofurantoin versus double antibiotic paste.

Official Title
-----------------
The Effectiveness of Single Antibiotic Paste Nitrofurantoin V/S Double Antibiotic Paste in Alleviation of Post-Operative Pain in Adult Patients Symptomatic Irreversible Pulpitis

Conditions
-----------------
Pain, Symptomatic Irreversible Pulpitis

Intervention / Treatment
-----------------
* Drug: Nitrofurantoin
* Drug: Double Antibiotic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No medical history no history of allergy to medications used in root canal treatment patients suffering from Symptomatic Irreversible Pulpitis Exclusion Criteria: Patients who were not suitable for conventional root canal treatment multirooted teeth

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nitrofurantoin<br> | Drug: Nitrofurantoin<br>* Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions<br>|
| Experimental: Double antibiotic paste<br> | Drug: Double Antibiotic<br>* DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To alleviate dental pain | Dental pain will be measured by using Visual Analogue Scale(VAS) which is an 10-point scale from 0-10 where 0 represents no pain and 10 represents the worst pain measured | 12 hours upto 72 hours following placement of intracanal medicament |
Sugammadex and Cognitive Function

Study Overview
=================
Brief Summary
-----------------
Post operative cognitive dysfunction (POCD) is recognized as a frequent complication after both cardiac and non cardiac surgery, affecting approximately 1/3 of the patients. The aim of this study is to examine the possible effect of the novel reversal agent sugammadex versus neostigmine/ atropine combination on cognitive function of adult patients after elective surgery during the early post operative period as well as at discharge.

Official Title
-----------------
Effect of Sugammadex Versus Neostigmine/Atropine Combination on Cognitive Function After Elective Adult Surgery

Conditions
-----------------
Post Operative Cognitive Dysfunction

Intervention / Treatment
-----------------
* Drug: Sugammadex
* Drug: Neostigmine/atropine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged >40 years old ASA I-III Patients scheduled for elective surgery with general anaesthesia. Exclusion Criteria: Neuro-, vascular-, orthopedic- or cardiac surgery Known psychiatric or disease of the CNS History of craniotomy Receiving tranquillisers or antidepressants on a regular basis pre-operatively Alcoholism or drug dependence History of stroke Refusal of patient Inability to read or write MMSE < 22 pre-operatively

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Sugammadex<br>Sugammadex is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery. | Drug: Sugammadex<br> <br> * Other names: Bridion;|
| Active Comparator: Neostigmine/atropine<br>Neostigmine combined to atropine is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery. | Drug: Neostigmine/atropine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the Mini-Mental State Evaluation test |  | Preoperatively, 1 hour postoperatively, at discharge (1-15 days postoperatively) | 
| Change in the clock-drawing test |  | Preoperatively, 1 hour postoperatively, at discharge (1-15 days postoperatively) | 
| Change in the Isaacs set test |  | Preoperatively, 1 hour postoperatively, at discharge (1-15 days postoperatively) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time from reversal agent administration to extubation |  | After reversal agent administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cognitive function
Molecular Modulation of the Growth Plate

Study Overview
=================
Brief Summary
-----------------
The researchers are trying to identify molecular mechanisms that control growth plate mediated limb growth and identify agents that can be used to enhance or slow growth.

Official Title
-----------------
Molecular Modulation of the Growth Plate

Conditions
-----------------
Growth Plate Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Skeletally immature children/adults undergoing surgical procedures where growth plate cartilage is removed as a normal part of their procedure; or patients undergoing surgical procedures where bone is removed as a normal part of their procedure. Exclusion Criteria: Skeletally mature children/adults
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RNA expression | Measure RNA levels in growth plate tissue samples (ng/mL) | End of Study (1/2019 |
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Official Title
-----------------
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Omalizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Allergic asthma patients Inadequately controlled patients Exclusion Criteria: - History of severe anaphylactoid or anaphylactic reactions Previous treatment with omalizumab History of cancer or cancer Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Omalizumab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of omalizumab |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary function parameters measured by spirometer |  |  | 
| Morning and evening peak expiratory flow (PEF) |  |  | 
| Symptoms score, treatment score, activities of daily living score, nighttime sleep score, and asthma score |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, IgE, Omalizumab
Testing Hypersensitivity to Metals in Sarcoidosis Patients by Applying the MELISA Test.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to apply the MELISA test, that diagnose hypersensitivity to metals, in Sarcoidosis patients with occupational exposure.

Detailed Description
-----------------
Peripheral blood from sarcoidosis patients with occupational anamnesis that involves exposure to metals will be sent to MELISA Medica in Stockholm Sweden. The MELISA test will examine hypersensitivity to metals that can be related to the granulomatous response of sarcoidosis.

Official Title
-----------------
Testing Hypersensitivity to Metals in Sarcoidosis Patients With Occupational Exposure, Using the MELISA Test.

Conditions
-----------------
Sarcoidosis

Intervention / Treatment
-----------------
* Other: MELISA test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy confirmed sarcoidosis Granulomatous disease Occupational anamnesis with exposure to metals Exclusion Criteria: Patients with interstitial disease No occupational anamnesis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: metal hypersensitivity<br>peripheral blood test for metal hypersensitivity (MELISA test) | Other: MELISA test<br>* MELISA test for hypersensitivity to metals in sarcoidosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MELISA test | Using the MELISA test in peripheral blood, in order to find hypersensitivity to metals that can be related to the granulomatous response of sarcoidosis. | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sarcoidosis, occupational exposure, MELISA
BOTOX® Prophylaxis in Patients With Chronic Migraine

Study Overview
=================
Brief Summary
-----------------
This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic migraine.

Conditions
-----------------
Migraine Disorders

Intervention / Treatment
-----------------
* Biological: botulinum toxin Type A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of chronic migraine Willing to use BOTOX® as preventative treatment for migraine Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| botulinum toxin Type A<br>155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year. | Biological: botulinum toxin Type A<br>* 155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.<br>* Other names: BOTOX®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence Rate of Dysphagia | Incidence rates are reported for subjects with events per 1,000 person-months and are based on the first reported occurrence of dysphagia from study enrollment up to 64 weeks. Dysphagia is difficulty or discomfort swallowing. | 64 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence Rate of Intractable Migraine | Incidence rates are reported for subjects with events per 1,000 person-months and are based on the first reported occurrence of intractable migraine from study enrollment up to 64 weeks. Intractable migraine is a migraine that does not seem to go away. | 64 weeks |
Prospective Study on the Incidence of Adrenal Crisis in Patients With Chronic Adrenal Insufficiency

Study Overview
=================
Brief Summary
-----------------
Prospective study to evaluate incidence, causes and potential risk factors for adrenal crisis in patients with chronic adrenal insufficiency.

Detailed Description
-----------------
This is a prospective study following patients with chronic adrenal insufficiency by contacting them every 6 months via questionnaires and telephone. QUestionnaires assess incidence and causes of adrenal crisis, frequency of hospitalization.

Official Title
-----------------
Prospective Cohort-study on the Incidence of Adrenal Crisis in Patients With Chronic Adrenal Insufficiency

Conditions
-----------------
Adrenal Insufficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic primary or secondary adrenal insufficiency requiring glucocorticoid substitution therapy Exclusion Criteria: adrenocortical carcinoma long term glucocorticoid treatment above 7.5 mg prednisone equivalent dose for other reasons than adrenal insufficiency age < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of adrenal crisis |  | during study period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | during study period |
Goals of Care Discussions for Hospitalized Patients With Advanced Cancer

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to better understand gender differences in end-of-life communication between physicians and patients with advanced cancer in the hospital.

Official Title
-----------------
Gender Differences in Inpatient Goals of Care Discussions in Patients With Advanced Cancer

Conditions
-----------------
Metastatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English speaking, have metastatic cancer that has progressed despite treatment Exclusion Criteria: Cognitive impairment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of end-of-life communication | This is a qualitative study and the outcome will be assessed by coding the transcripts of the goals of care discussions. We will use the Roter Interaction Analysis System (RIAS) in which coders assign 1 of 37 mutually exclusive and exhaustive categories to each complete thought expressed (referred to as an utterance). Utterances are combined to reflect instrumental (e.g., biomedical exchange, psychosocial exchange, and partnership building) and affective behaviors (e.g., social conversation, positive and negative statements, and emotional statements). Additional global measures include patient-centeredness, verbal dominance, and tone. | 15 months |